Industry News

Cipla USA Inc. the wholly owned subsidiary of Cipla Limited(BSE: 500087; NSE: CIPLA; and hereafter referred to as "Cipla") today announced the launch of Liraglutide Injection, 18 mg/3 mL (6 mg/mL) single-patient-use prefilled pens, the generic equivalent of Saxenda® (liraglutide injection).

Novartis today announced plans to establish a new 46,000-square-foot radioligand therapy (RLT) manufacturing facility in Denton, Texas, as part of its broader strategy to expand advanced cancer treatment capabilities across the United States.

AstraZeneca announced that the U.S. Food and Drug Administration has approved its fixed-duration all-oral combination of Calquence® (acalabrutinib) with venetoclax for the first-line treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in adults. The approval marks the first time a Bruton’s tyrosine kinase (BTK) inhibitor-based regimen has been authorised in the U.S. as a time-limited, oral treatment option for newly diagnosed patients.

Sai Life Sciences Limited has announced an ambitious recruitment drive to hire more than 700 scientific, technical and management professionals in the 2026–27 financial year as it scales up operations to meet growing global demand for drug discovery, development and manufacturing services.

Gilead Sciences today announced a definitive agreement to acquire Arcellx in a transaction valued at approximately USD 7.8 billion, marking a major step in Gilead’s expansion in next-generation cell therapy.